Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9512165 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
US11236121 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
Aug, 2037
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10342810 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
US10172871 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Treatment: Method of treating postpartum depression
Dosage: CAPSULE;ORAL